The ability to monitor biologic candidates' propensity towards self-association is considered critical for predicting whether a therapeutic is likely to aggregate or become difficult to administer due to viscosity.
Because it is neither practical nor cost-effective to consume large quantities of material early in development, measurements are conducted at low concentrations and used to predict how a formulation will behave at higher, more clinically-relevant concentrations.
Precise and reproducible data for these measurements is required for rational decision-making that improves downstream success.
Read how Merck KGaA uses deviation from linearity derived from light scattering measurements to find the optimal formulation buffer for their biologics candidates, and how these measurements on the Prometheus Panta compare to previously collected data.
